A Life-changing Way to Treat COPD/ Emphysema

FDA approved in 2018, with over 20,000 patients treated globally, the Zephyr Valve is proven to help improve your patient’s lung function, exercise capacity and quality of life—without surgery and many of its associated risks.20

If you treat patients with severe COPD and emphysema, we’re here to help. Request a call to speak to a Zephyr Valve representative in your area.

Evidence A 2020 Gold Update

GOLD 2020:  Level A Evidence rating affirms that endobronchial valves, like the Zephyr Valve, are a viable, minimally invasive treatment option for severe emphysema, a form of COPD.

Help-Patients-COPD-Breathe-Easier-2

Patient Selection

Who Qualifies for the Zephyr Valve?

Patients who meet the following criteria should be evaluated for treatment with endobronchial valves:1-5

  • Breathless despite optimal medical management (mMRC≥2)
  • A confirmed diagnosis of COPD
  • Non-smoking or willing to quit smoking
  • Have an FEV1 ≤50% predicted

For more detailed information on clinical data and patient selection criteria please download our free resources.

How It Works

Non-surgical. Non-drug.

The Zephyr Lung Valve is a new category of treatment for COPD and emphysema. Despite taking the best available medications, many patients with emphysema are still short of breath. This is caused by hyperinflation of the lungs and depression of the diaphragm.

The Zephyr Valves reduce lung hyperinflation by allowing trapped air to escape and preventing new air from entering that diseased lobe. The remaining lobes are then able to expand more fully and work more efficiently, reducing pressure on the diaphragm and improving overall lung function.

How-Zephyr-Valve-Works-COPD-Emphysema
Treatment-Continuum-COPD

If you’d like to learn more about how the Zephyr Endobronchial Valve
treatment can help your patients, our dedicated specialists are here to help.

Patient Benefits

Helping Patients Combat Breathlessness

As symptoms of COPD become more severe, medications and oxygen therapy are often not enough. Lung volume reduction surgery is a big decision that comes with many associated risks. Zephyr Valves provide a minimally invasive alternative that can improve lung function and quality of life without the need for lung volume reduction surgery or lung transplantation.1 

Progression of COPD and Emphysema
Zephyr-Treatment-Benefits

If you’re ready to start the referral process, we’re happy to help.

Clinical Evidence

The Zephyr Endobronchial Valve
Shows Clinically Significant Benefits

  • 4 randomized clinical trials published using preselection tools to qualify appropriate patients1-5
  • Published in the New England Journal of Medicine, The Lancet, and The American Journal of Respiratory and Critical Care Medicine1-5
  • Statistically significant and clinically meaningful improvements compared to standard of care in multiple trials1-4
  • GOLD 2020:  Level A Evidence rating
  • Treatment success seen in a broad range of primary and secondary endpoints1-5

RCTDesignSample size & follow-up periodProcedural Success (TLVR%)Difference Zephyr Valve vs. Control Groups (ITT)
Lung
function
(fev1%)
MCID = 10%-15%
Excercise capacity
(6mwd)
MCID = 26 m
quality
of life
(sgrq)
MCID = -4 pts
LIBERATE12:1 Randomization
Heterogeneous only
Multicenter
n=190
12 months
84%18.0%
p<0.001
39 m
p=0.002
-7.1 pts
p=0.004
TRANSFORM22:1 Randomization
Heterogeneous only
Multicenter
n=97
6 months
90%29.3%
p<0.001
79 m
p<0.001
-6.5 pts
p=0.031
IMPACT31:1 Randomization
Homogeneous only
Multicenter
n=93
6 months*
89%16.3%
p<0.001
28 m
p=0.016
-7.5 pts
p<0.001
STELVIO4,51:1 Randomization
Heterogeneous & Homogeneous
Single Center
n=68
6 months
88%17.8%
p=0.001
74 m
p<0.001
-14.7 pts**
p<0.001

*Data on file at PMX (not in publication)
**Completed cases, all other values listed are ITT population
T Difference between valve and control groups
Pulmonx-Zephyr-Clinical-Study-Summary-Table

If you have a patient with COPD that you would like to have
evaluated for treatment with the Zephyr Valve, please connect with us.

Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

See What Zephyr Valve Patients are Saying

20,000 People Have Been Treated with the Zephyr Valve

Shelley-Zephyr-Valve-Success

My pulmonologist, Dr. Teresa Heatly, first mentioned the Zephyr Valves to me because she thought I might be a candidate. I really trust her, and I was definitely interested in anything that might help.”

–Shelley, 62

Donald-Zephyr-Valve-Success

“ It’s been four months and I am shocked at how good I am breathing. I can have a long phone conversation, walk outside to get the mail, change the bedsheets, and do it all without oxygen.”

–Donald, 67

Mike-Zephyr-Valve-Success

The procedure went well and frankly was much easier than the huge surgery I had been preparing for before the valves were an option.”

–Mike, 65

Still have questions? We’re here to help.

Treat COPD
© 2021 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners. GLO-EN-787-v2 (v2.0)
Privacy Policy | Terms of Use | Sitemap | Prescriptive Information | In The News | Contact Us
Logo-RGB
United States Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.
Caution: Federal law restricts this device to sale by or on the order of a physician.
International Brief Statement: The Zephyr® Endobronchial Valve is an implantable bronchial valve intended to control airflow in order to improve lung functions in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; Evidence of active pulmonary infection; Patients with known allergies to Nitinol (nickeltitanium) or its constituent metals (nickel or titanium); Patients with known allergies to silicone; Patients who have not quit smoking. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Privacy Preference Center